A Phase IIB, Randomized, Double-blind,Placebo-controlled study to evaluate the neutralization of the interferon gene signature and the clinical efficacy of IFNα-Kinoid in adult subjects with systemic Lupus Erythematosus

计划入组 21 人

Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

计划入组 185 人 · 首次发布于 2016 年 1 月 27 日

Vaccination In Pregnancy Gene Signature: VIP Signature Study

计划入组 30 人 · 首次发布于 2017 年 9 月 15 日

SIG001 (Signature Biologics)

pegylated integrated interferon mutant

Gene therapy (IL-12/IFN-alpha, PINC), Valentis

Signature Therapeutics, Inc.

United States

SIGNATURE PHYTOCHEMICAL INDUSTRIES

India

JIUYUAN GENE

Liquid Fat Supplement Shows Promise in Treating Rare Childhood Disease Ataxia-Telangiectasia

Merck's Enpatoran Shows Promise for Lupus Rash in Phase 2 Trial Despite Mixed Results

Cenerimod Demonstrates Reduced Interferon Signatures in Phase 2b SLE Trial